PMID- 26075286
OWN - NLM
STAT- MEDLINE
DCOM- 20160203
LR  - 20240324
IS  - 2314-6753 (Electronic)
IS  - 2314-6745 (Print)
VI  - 2015
DP  - 2015
TI  - The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A 
      "Me Too" or "the Special One" Antidiabetic Class?
PG  - 806979
LID - 10.1155/2015/806979 [doi]
LID - 806979
AB  - Incretin-based therapies, the most recent therapeutic options for type 2 diabetes 
      mellitus (T2DM) management, can modify various elements of the disease, including 
      hypersecretion of glucagon, abnormal gastric emptying, postprandial 
      hyperglycaemia, and, possibly, pancreatic beta cell dysfunction. Dipeptidyl 
      peptidase-4 (DPP-4) inhibitors (gliptins) increase glucagon-like peptide-1 
      (GLP-1) availability and correct the "incretin defect" seen in T2DM patients. 
      Clinical studies have shown good glycaemic control with minimal risk of 
      hypoglycaemia or any other adverse effects, despite the reports of pancreatitis, 
      whose association remains to be proved. Recent studies have been focusing on the 
      putative ability of DPP-4 inhibitors to preserve pancreas function, in particular 
      due to the inhibition of apoptotic pathways and stimulation of beta cell 
      proliferation. In addition, other cytoprotective effects on other organs/tissues 
      that are involved in serious T2DM complications, including the heart, kidney, and 
      retina, have been increasingly reported. This review outlines the therapeutic 
      potential of DPP-4 inhibitors for the treatment of T2DM, focusing on their main 
      features, clinical applications, and risks, and discusses the major challenges 
      for the future, in particular the possibility of becoming the preferred therapy 
      for T2DM due to their ability to modify the natural history of the disease and 
      ameliorate nephropathy, retinopathy, and cardiovascular complications.
FAU - Godinho, Ricardo
AU  - Godinho R
AD  - Laboratory of Pharmacology and Experimental Therapeutics, Institute for 
      Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, Coimbra 
      University, 3000-548 Coimbra, Portugal.
FAU - Mega, Cristina
AU  - Mega C
AUID- ORCID: 0000-0002-9913-875X
AD  - Laboratory of Pharmacology and Experimental Therapeutics, Institute for 
      Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, Coimbra 
      University, 3000-548 Coimbra, Portugal ; ESAV, Polytechnic Institute of Viseu, 
      3504-510 Viseu, Portugal.
FAU - Teixeira-de-Lemos, Edite
AU  - Teixeira-de-Lemos E
AUID- ORCID: 0000-0002-6346-8319
AD  - Laboratory of Pharmacology and Experimental Therapeutics, Institute for 
      Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, Coimbra 
      University, 3000-548 Coimbra, Portugal ; ESAV, Polytechnic Institute of Viseu, 
      3504-510 Viseu, Portugal.
FAU - Carvalho, Eugenia
AU  - Carvalho E
AD  - Center for Neuroscience and Cell Biology-Institute for Biomedical Imaging and 
      Life Sciences (CNC.IBILI) Research Unit, University of Coimbra, 3000-548 Coimbra, 
      Portugal ; The Portuguese Diabetes Association (APDP), 1250-189 Lisbon, Portugal.
FAU - Teixeira, Frederico
AU  - Teixeira F
AD  - Laboratory of Pharmacology and Experimental Therapeutics, Institute for 
      Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, Coimbra 
      University, 3000-548 Coimbra, Portugal.
FAU - Fernandes, Rosa
AU  - Fernandes R
AUID- ORCID: 0000-0001-7828-2296
AD  - Laboratory of Pharmacology and Experimental Therapeutics, Institute for 
      Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, Coimbra 
      University, 3000-548 Coimbra, Portugal ; Center for Neuroscience and Cell 
      Biology-Institute for Biomedical Imaging and Life Sciences (CNC.IBILI) Research 
      Unit, University of Coimbra, 3000-548 Coimbra, Portugal.
FAU - Reis, Flavio
AU  - Reis F
AUID- ORCID: 0000-0003-3401-9554
AD  - Laboratory of Pharmacology and Experimental Therapeutics, Institute for 
      Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, Coimbra 
      University, 3000-548 Coimbra, Portugal ; Center for Neuroscience and Cell 
      Biology-Institute for Biomedical Imaging and Life Sciences (CNC.IBILI) Research 
      Unit, University of Coimbra, 3000-548 Coimbra, Portugal.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150517
PL  - England
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
SB  - IM
MH  - Blood Glucose/*metabolism
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Humans
MH  - Hyperglycemia/*drug therapy/metabolism
MH  - Insulin-Secreting Cells/metabolism
PMC - PMC4449938
EDAT- 2015/06/16 06:00
MHDA- 2016/02/04 06:00
PMCR- 2015/05/17
CRDT- 2015/06/16 06:00
PHST- 2015/01/11 00:00 [received]
PHST- 2015/04/09 00:00 [revised]
PHST- 2015/04/11 00:00 [accepted]
PHST- 2015/06/16 06:00 [entrez]
PHST- 2015/06/16 06:00 [pubmed]
PHST- 2016/02/04 06:00 [medline]
PHST- 2015/05/17 00:00 [pmc-release]
AID - 10.1155/2015/806979 [doi]
PST - ppublish
SO  - J Diabetes Res. 2015;2015:806979. doi: 10.1155/2015/806979. Epub 2015 May 17.